AstraZeneca PLC

AZN

GB0009895292

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Employees

89,900

Sector

Pharmaceuticals

Calendar

06:07pm - World Lung Cancer Conference - Abstract No #MA17.04

Related indices

STOXX Europe 600 Index (EUR) , FTSE 100

More about the company

Income Statement and Estimates

More financial data

Analysis / Opinion

ASTRAZENECA : Healthy operational momentum sustained in Q2

July 26, 2024 at 12:10 pm EDT

'Another Good Year' Ahead for AstraZeneca: CEO Pascal Soriot

February 09, 2023 at 10:04 am EST

More Strategies

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

162.03USD

Average target price

184.20USD

Spread / Average Target

+13.69%

Consensus

Profit revisions

Estimate revisions

Quarterly earnings, Rate of surprise

Company calendar

Market Closed - London S.E. Other stock markets 11:35:10 2024-09-10 am EDT			5-day change	1st Jan Change
12,406.00 ^GBX	-2.41%		-6.55%	+17.04%

Sep. 10	AstraZeneca 'Working Very Closely' With Chinese Authorities on Probe, CEO Tells Bloomberg	MT
Sep. 10	European Equities Close Lower in Tuesday Trading; Apple, Google Lose Appeals Against European Commission	MT

AstraZeneca 'Working Very Closely' With Chinese Authorities on Probe, CEO Tells Bloomberg	Sep. 10	MT
European Equities Close Lower in Tuesday Trading; Apple, Google Lose Appeals Against European Commission	Sep. 10	MT
British Equities Retreat on Fresh UK Labor Market Data	Sep. 10	MT
European shares drop while BMW skids into reverse	Sep. 10	AN
Sophia Genetics Partners with AstraZeneca on Expanding Global Access to Liquid Biopsy Testing Option	Sep. 10	MT
ASTRAZENECA : Stifel confirms its recommendation on the stock	Sep. 10	CF
SOPHiA GENETICS and AstraZeneca Collaborate to Further Expand Global Access to Liquid Biopsy Testing	Sep. 10	CI
ASTRAZENECA : disappointing test, Oddo BHF remains 'neutral	Sep. 10	CF
ASTRAZENECA : Goldman Sachs reiterates its Buy rating	Sep. 10	ZD
Pascal Soriot, CEO of AstraZeneca : New lung cancer treatment shows two-month improvement in survival	Sep. 10	MT
Four steps back, one step forward	Sep. 10
ASTRAZENECA : UBS remains Sell on clinical trial results	Sep. 10	CF
Shares mixed as investors await US inflation	Sep. 10	AN
AstraZeneca Shares Slump After Cancer Drug Misses Key Target	Sep. 10	DJ
AstraZeneca share price falls, clinical trial unconvincing	Sep. 10	CF
AstraZeneca shares drop as lung cancer drug trial fails to improve survival	Sep. 10	RE
European stocks mixed before eyes turn stateside	Sep. 10	AN
FTSE 100 falls as AstraZeneca weighs; slowing wage growth cements rate cut bets	Sep. 10	RE
European shares hold ground as AstraZeneca drags, tech shares rise	Sep. 10	RE
AstraZeneca, Daiichi Sankyo's Lung Cancer Treatment Shows Promising Response Rates in Combination With Imfinzi	Sep. 10	MT
AstraZeneca, Daiichi Sankyo's Lung Cancer Treatment Fails to Exhibit Significant Overall Survival Rate	Sep. 10	MT
Health Care Up on Cyclical Bias -- Health Care Roundup	Sep. 09	DJ
Transcript : AstraZeneca PLC - Special Call	Sep. 09
AstraZeneca says lung cancer drug trial shows no significant improvement in overall survival	Sep. 09	RE
The market burns its idols	Sep. 09

AstraZeneca PLC

Equities

AZN